{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:11:50Z","timestamp":1793362310387,"version":"4.5.0"},"reference-count":27,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2020,2,1]]},"DOI":"10.1001\/jamaneurol.2019.3365","type":"journal-article","created":{"date-parts":[[2019,10,7]],"date-time":"2019-10-07T11:31:41Z","timestamp":1570447901000},"page":"184","source":"Crossref","is-referenced-by-count":486,"title":["Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies"],"prefix":"10.1001","volume":"77","author":[{"given":"Gustavo","family":"Luna","sequence":"first","affiliation":[{"name":"Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Alping","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden"},{"name":"Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Burman","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Fink","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Fogdell-Hahn","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gunnarsson","sequence":"additional","affiliation":[{"name":"Center for Health and Medical Psychology, \u00d6rebro University, \u00d6rebro, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Hillert","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Langer-Gould","sequence":"additional","affiliation":[{"name":"Clinical and Translational Neuroscience, Southern California Permanente Medical Group, Kaiser Permanente, Pasadena"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Lycke","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience and Rehabilitation, University of Gothenburg, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Nilsson","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Division of Neurology, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonatan","family":"Salzer","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Clinical Neuroscience, Umea University, Umea, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Svenningsson","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Vrethem","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Linkoping University, Linkoping, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Olsson","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Piehl","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden"},{"name":"Department of Neurology, Karolinska University Hospital, Stockholm, Sweden"},{"name":"Academic Specialist Center, Stockholm Health Services, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Frisell","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"noi190084r1","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/joim.12203","article-title":"Established and novel disease-modifying treatments in multiple sclerosis.","volume":"275","author":"Cross","year":"2014","journal-title":"J Intern Med"},{"issue":"4","key":"noi190084r2","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/joim.12204","article-title":"A changing treatment landscape for multiple sclerosis: challenges and opportunities.","volume":"275","author":"Piehl","year":"2014","journal-title":"J Intern Med"},{"issue":"8","key":"noi190084r3","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/ene.2013.20.issue-8","article-title":"Hospital admission due to infections in multiple sclerosis patients.","volume":"20","author":"Montgomery","year":"2013","journal-title":"Eur J Neurol"},{"issue":"3","key":"noi190084r4","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/ane.2017.136.issue-3","article-title":"Safety concerns and risk management of multiple sclerosis therapies.","volume":"136","author":"Soelberg Sorensen","year":"2017","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"noi190084r5","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nrneurol.2016.21","article-title":"Disease-modifying therapies and infectious risks in multiple sclerosis.","volume":"12","author":"Winkelmann","year":"2016","journal-title":"Nat Rev Neurol"},{"issue":"11","key":"noi190084r6","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s11910-017-0800-8","article-title":"Infections in patients receiving multiple sclerosis disease-modifying therapies.","volume":"17","author":"Grebenciucova","year":"2017","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"5","key":"noi190084r7","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.","volume":"362","author":"Cohen","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"noi190084r9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1001\/jamaneurol.2014.3065","article-title":"Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management.","volume":"72","author":"Arvin","year":"2015","journal-title":"JAMA Neurol"},{"issue":"10","key":"noi190084r11","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1136\/jnnp-2017-317493","article-title":"Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study.","volume":"89","author":"Wijnands","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"20","key":"noi190084r12","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1212\/WNL.0000000000003331","article-title":"Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy.","volume":"87","author":"Salzer","year":"2016","journal-title":"Neurology"},{"issue":"3","key":"noi190084r13","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis.","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"noi190084r14","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis.","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med"},{"issue":"199","key":"noi190084r15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/ane.12425","article-title":"The Swedish MS registry\u2014clinical support tool and scientific resource.","volume":"132","author":"Hillert","year":"2015","journal-title":"Acta Neurol Scand"},{"issue":"2","key":"noi190084r16","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/EDE.0000000000000948","article-title":"Validation of the Swedish Multiple Sclerosis Register: further improving a resource for pharmacoepidemiologic evaluations.","volume":"30","author":"Alping","year":"2019","journal-title":"Epidemiology"},{"key":"noi190084r18","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register.","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Public Health"},{"issue":"7","key":"noi190084r19","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/(ISSN)1099-1557","article-title":"The new Swedish Prescribed Drug Register--opportunities for pharmacoepidemiological research and experience from the first six months","volume":"16","author":"Wettermark","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"15","key":"noi190084r20","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1002\/sim.3618","article-title":"Imputing missing covariate values for the Cox model.","volume":"28","author":"White","year":"2009","journal-title":"Stat Med"},{"key":"noi190084r21","first-page":"699","article-title":"A Swedish nationwide pharmaco-epidemiological and genetic study of the long-term safety and effectiveness of natalizumab (IMSE 1).","volume":"24","author":"Kagstrom","year":"2018","journal-title":"Mult Scler J"},{"key":"noi190084r22","first-page":"696","article-title":"A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of fingolimod (IMSE 2).","volume":"24","author":"Falt","year":"2018","journal-title":"Mult Scler J"},{"issue":"6","key":"noi190084r23","first-page":"905","article-title":"Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.","volume":"77","author":"Rutherford","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"noi190084r24","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1136\/annrheumdis-2018-214326","article-title":"Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden.","volume":"78","author":"Gr\u00f8n","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"noi190084r25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087379","article-title":"Safety with ocrelizumab in rheumatoid arthritis: results from the ocrelizumab phase III program.","volume":"9","author":"Emery","year":"2014","journal-title":"PLoS One"},{"issue":"1-2","key":"noi190084r26","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jns.2015.04.010","article-title":"Rituximab treatment did not aggravate ongoing progressive multifocal leukoencephalopathy in a patient with multiple sclerosis.","volume":"353","author":"Asztely","year":"2015","journal-title":"J Neurol Sci"},{"key":"noi190084r27","first-page":"299","article-title":"Reduction of the risk of PML in natalizumab treated MS patients in Sweden: an effect of JCV ab index surveillance.","volume":"24","author":"Kagstrom","year":"2018","journal-title":"Mult Scler J"},{"key":"noi190084r8","unstructured":"Tysabri? EMA. EPAR product information. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tysabri-epar-product-information_en.pdf. Accessed March 14, 2019."},{"key":"noi190084r10","unstructured":"Gilenya? EMA. EPAR product information. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/gilenya-epar-product-information_en.pdf. Accessed March 14, 2019."},{"key":"noi190084r17","unstructured":"Socialstyrelsen. Sjukdomar i sluten v\u00e5rd, 1987\u20132010: Inpatient Diseases in Sweden 1987-2008. https:\/\/www.socialstyrelsen.se\/globalassets\/sharepoint-dokument\/artikelkatalog\/statistik\/2011-9-5.pdf. Published 2008. Accessed September 4, 2019."}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2752284\/jamaneurology_luna_2019_oi_190084_1630696216.93896.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T11:06:17Z","timestamp":1631012777000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2752284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,1]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2019.3365","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2,1]]}}}